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Abstract
Background: Adverse outcomes occurring early after antiretroviral therapy (ART) initiation are common in sub-Saharan
Africa, despite reports of high levels of ART adherence in this setting. We sought to determine the relationship between very
early ART adherence and early adverse outcomes in HIV-infected adults in Botswana.
Methods: This prospective cohort study of 402 ART-naı ¨ve, HIV-infected adults initiating ART at a public HIV clinic in
Gaborone, Botswana evaluated the relationship between suboptimal early ART adherence and HIV treatment outcomes in
the initial months after ART initiation. Early adherence during the interval between initial ART dispensation and first ART
refill was calculated using pill counts. In the primary analysis patients not returning to refill and those with adherence ,0.95
were considered to have suboptimal early adherence. The primary outcome was death or loss to follow-up during the first 6
months of ART; a secondary composite outcome included the primary outcome plus incident opportunistic illness (OIs) and
virologic failure. We also calculated the percent of early adverse outcomes theoretically attributable to suboptimal early
adherence using the population attributable risk percent (PAR%).
Results: Suboptimal early adherence was independently associated with loss to follow-up and death (adjusted OR 2.3, 95%
CI 1.1–4.8) and with the secondary composite outcome including incident OIs and virologic failure (adjusted OR 2.6, 95% CI
1.4–4.7). However, of those with early adverse outcomes, less than one-third had suboptimal adherence and approximately
two-thirds achieved virologic suppression. The PAR% relating suboptimal early adherence and primary and secondary
outcomes were 14.7% and 17.7%, respectively.
Conclusions: Suboptimal early adherence was associated with poor outcomes, but most early adverse outcomes occurred
in patients with optimal early adherence. Clinical care and research efforts should focus on understanding early adverse
outcomes that occur despite optimal adherence.
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Introduction
Death in the initial months after initiating combination
antiretroviral therapy (ART), often termed ‘‘early mortality,’’
accounts for the majority of all first-year deaths in adult
HIV treatment programs in resource-limited settings [1–3].
However, published data indicate that ART adherence is high
in the very settings most affected by high rates of early
mortality [4]. This suggests that classic mechanisms of HIV
treatment failure, whereby suboptimal ART adherence leads
to AIDS progression and death, may not predominate as a
cause of early events.
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20010More broadly, adherence as well as virologic and immunologic
responses to ART among patients who suffer early mortality after
ART initiation remains largely uncharacterized, in part because
many events occur before these measures can be obtained.
Nonetheless, understanding response to ART in these individuals
is important for the design of interventions aimed at reducing early
mortality. For example, patients may have difficulty tolerating
medications early during therapy, leading to failure to respond
virologically and immunologically and subsequent disease pro-
gression [5]. Alternatively, patients may experience poor outcomes
despite high adherence levels, perhaps due to suboptimal
immunologic responses despite virologic suppression [6], rapid
immune response and inflammation [7,8], drug toxicity or other
factors [9]. Landmark studies documenting the importance of
initial ART response to subsequent survival have usually measured
initial response several months after ART initiation, after the
majority of very early deaths occur, and therefore do not inform
the relationship between virological and immunological response
to ART and early mortality [10,11]. Thus, a fundamental
understanding of how response to ART relates to early mortality
is needed to improve programmatic outcomes overall.
Adherence is strongly related to clinical outcomes and is the first
step in responding to ART [12]. However, longitudinal studies
evaluating adherence-outcome relationships often by design
require minimum follow-up time to be included in analyses,
which excludes patients who die or are lost to follow-up early after
ART initiation [13–18]. As a result, estimates of the strength of the
relationship between initial ART adherence and risk of early
outcomes, as well as the proportion of early events associated with
suboptimal early adherence, have not been well characterized. If
the proportion of early adverse outcomes within a population that
are attributable to early suboptimal adherence is low, then patient
care and research efforts should include a focus on factors besides
adherence when assessing patients who clinically worsen in the
early stages of treatment.
In previous studies in Botswana we have documented that the
vast majority of deaths in the first year after starting ART occur in
the initial months of treatment and that the median adherence
level measured approximately 6 months after ART initiation is
high (91%) [13,19]. We therefore hypothesized that most early
deaths were occurring despite high levels of adherence and,
potentially, virologic response. To investigate this further, we
evaluated the relationship between the earliest routinely available
objective measure of early ART adherence and risk of early
adverse outcomes after ART initiation in a sub-Saharan African
setting. Goals of our analysis were to include patients who suffered
events very early after ART initiation in order to obtain a range of
risk estimates within which the true relationship between early
adherence and early outcomes is likely to exist, to estimate the
proportion of early events in the population potentially attribut-
able to suboptimal early adherence, and to describe virologic
responses among those suffering early adverse outcomes.
Methods
Study Setting and Participants
This prospective observational cohort study evaluated the
relationship between early suboptimal adherence and early
adverse outcomes among ART-naı ¨ve, HIV-infected adults aged
18 years and older initiating free ART at the Infectious Disease
Care Center (IDCC) at Princess Marina Hospital (PMH) in
Gaborone, Botswana. The IDCC at PMH is a large public HIV
clinic where HIV-infected individuals with CD4 counts ,200
cells/mm
3 or a qualifying opportunistic illness (OI) were provided
with free ART [19,20]. Patients saw medical doctors with training
in HIV care, including diagnosis and treatment of OIs. Initial
ART regimens recommended as first-line therapy were fixed-dose
combination zidovudine-lamivudine plus either efavirenz (for
women of non-reproductive potential or men) or nevirapine,
although other ART medications were available. ART was
dispensed on-site. Guidelines recommended HIV-1 RNA levels
(viral loads) at baseline, 3 months and then every 6 months
thereafter. All care was provided free of charge.
Early Adherence and Outcome Definitions
Early adherence was determined using pill counts performed
by study staff at the time of initiation and first ART refill, given
data indicating that pharmacy adherence measures such as pill
counts consistently predict outcomes and are more accurate than
self-report [12]. Specifically, the number of days of ART
dispensed to the patient at the time of starting ART was
calculated using the prescribed daily dose and the number of pills
of a single index ART medication in the regimen (e.g., efavirenz
for those on an efavirenz-containing ART regimen). The number
of days of the index medication that the patient returned with at
the time of the first ART refill was then determined by pill count
and subtracted from the number of days of ART initially
dispensed to arrive at the estimated number of days of ART
taken between initiation and first ART refill. The number of days
of ART taken during this interval was then divided by the
number of days between the date of ART initiation and the
actual date of the first ART refill to arrive at the estimated early
ART adherence. Patients were considered to have suboptimal
early adherence (present or absent) if their early adherence value
was ,0.95 based on previous research relating refill adherence to
virologic failure in this setting [13].
Loss to follow-up or death after ART initiation were considered
together as the primary composite outcome given a strong
documented relationship between loss to follow-up and death in
this specific setting as well as several others [19,21]. Secondary
outcomes evaluated included death alone (ie, not counting loss to
follow-up as an outcome) and a composite outcome including
virologic failure or incident OIs in addition to the primary
outcome. Loss to follow-up was defined as failure to locate the
patient before completion of the study after 3 phone calls to the
patient or their contacts on separate days, one home visit and
absence of patient interactions with other area clinics. Virologic
failure was defined as failure to achieve a viral load ,1,000
copies/mL either a) after at least 3 months of ART or b) for those
with more than 1 viral load measured at least 3 months after ART,
at the time of the last viral load measurement. Incident OIs were
defined as any World Health Organization (WHO) clinical stage 3
or 4 illness newly diagnosed after the baseline visit [22].
Data Collection
Study staff approached patients during clinic visits. Patients
providing written informed consent in English or Setswana were
assessed prior to ART initiation and then monthly thereafter until
approximately 6 months after ART initiation. Practically, patient
follow-up was considered complete when individuals had
completed the baseline visit plus 5 monthly follow-up visits
scheduled after ART initiation. Data on viral loads, CD4+ Tc e l l
(CD4 cell) counts and clinical diagnoses were abstracted from
paper or electronic medical records using study-specific forms.
ART medication names, doses, number of pills dispensed and
returned and dates of dispensation were obtained from the IDCC
pharmacy. The date of loss to follow-up was the date of the
patient’s last contact with the clinic, laboratory or pharmacy.
Antiretroviral Therapy Adherence and Early Outcomes
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home address where they could be reached, and patients were
actively traced via phone if they missed a clinic visit. If patients
were unable to be reached by phone on three separate days, the
study team performed a home visit in an effort to locate the
patient. Deaths and dates of death were confirmed by the
patients’ medical records or by patient contact report. Records of
patients with incident OIs were reviewed by study staff blinded to
patient adherence status to ascertain if the OI was under
evaluation prior to ART initiation. If this blinded review
suggested that the OI was present at baseline but undiagnosed
(e.g., sputum smear was sent at a baseline visit for cough but not
returned positive until a later visit), it was categorized as
prevalent. Diagnoses of TB and other OIs were not always
confirmed microbiologically. Data were entered into a Microsoft
Access database using double data entry.
Data Analysis
Patients were included in the analyses if they had non-missing
baseline initial ART regimen data of start date, pills dispensed,
drug names and doses. The vast majority of deaths in the first year
after ART initiation occur in the first several months after
treatment is begun, and mortality rates among those who survive
this initial early treatment period decrease substantially thereafter
[1]. Thus, early mortality can be thought of as a dichotomous
outcome that either occurs or does not, and time to early
mortality, which could be evaluated using survival analyses, is less
relevant. Thus, adherence and baseline characteristics were
related to primary (death or loss to follow-up) and secondary
adverse outcomes (death, loss to follow-up, incident OI, or
virologic failure) using relative risks (RR) with 95% confidence
intervals (CI). For patients with multiple secondary adverse
outcomes, the initial adverse outcome was used for the analysis.
A secondary analysis also evaluated the results when limiting the
primary outcome to death (ie, not counting loss to follow-up as an
event). Potential confounders included any variable present at
baseline and associated with either adherence or outcome at a p-
value of 0.20 or less. These factors were to be included in a final
logistic regression model if their inclusion changed the unadjusted
odds ratio (OR) for adherence and outcomes by 15% or more. We
chose to perform logistic regression rather than methods for
survival analysis because our primary aim was to relate occurrence
of early adverse outcomes to early adherence during the initial
period of ART, and was not to compare time-to-event by
adherence.
A challenge inherent in determining the relationship between
early adherence and early outcomes is that some patients initiate
ART and never return, in which case their adherence is unknown.
Requiring patients to return for at least one ART refill in order to
be included in the study would eliminate such patients from the
analysis but could introduce potentially severe selection bias due to
the relationship between loss to follow-up and death [21]. We
therefore chose to include these individuals, and in the primary
analysis the adherence of patients who initiated but never returned
for ART was imputed as ,0.95 (suboptimal), which is a
‘‘missing=failure’’ approach taken by others [23,24]. To evaluate
the effects of this assumption on the results we then performed a
sensitivity analysis repeating the primary analysis after recategor-
izing these patients’ adherence as $0.95 (optimally adherent).
Because all patients who initiated and never returned were
counted as outcomes, the primary analysis counting these patients
as suboptimally adherent was considered representative of the
strongest likely relationship between early adherence and early
adverse outcomes in the cohort.
Most studies relating adherence to outcomes have expressed this
relationship in terms of odds ratios, relative risks or relative
hazards [12]. These measures of association express the etiologic
relationship between exposure and outcome but do not convey the
overall public health importance of a risk factor to occurrence of
an outcome at the population level. To estimate the percentage of
early adverse outcomes theoretically attributable to suboptimal
early adherence, we calculated a population attributable risk
percentage (PAR%) using the equation: PAR%={[Pexp(RR21)]/
[Pexp(RR21)+1]} * 100 where Pexp=prevalence of suboptimal
adherence in the population, and RR=unadjusted relative risk of
early adverse outcomes among patients with suboptimal adher-
ence [25]. In this case, PAR% represents the percentage of early
adverse outcomes in the entire cohort that theoretically would not
have occurred if suboptimal early adherence was completely
eliminated [26]. We also described the proportion of patients with
specific initial adverse outcomes (e.g., death, incident OI) who
achieved a viral load #400 copies/mL during follow-up, as well as
the timing of their virologic response in relation to their initial
outcomes. Finally, data on illnesses considered contributing to
death among those who died were collected from patient medical
records or patient contacts.
Analyses were done using SAS 9.1 (SAS Institute Inc.), Cary,
North Carolina, USA. The research ethics boards of the Botswana
Ministry of Health, the PMH and the University of Pennsylvania
approved this research protocol.
Results
Characteristics of the cohort
Between May 31, 2005 and November 19, 2007, 474 patients
were enrolled. Of these, 40 (8%) were later found to be ineligible
because they were not ART naı ¨ve, 28 (6%) had missing initial ART
regimendata and 2(,1%)withdrew,leaving402 (85%)foranalysis.
The median date of enrollment was December 31, 2006 and the
median follow-up time was 256 days (interquartile range (IQR) 180
to 344 days), reflecting the observed variability in actual time to
completing 5 follow-up visits in the study. Baseline characteristics of
the cohort are shown in Table 1. The median baseline CD4 count
was 132 cells/mL
3 (IQR 73–180). Forty of 45 patients (89%) being
treated for active TB at baseline, and 288 of 321 patients (90%) who
were not being treated for active TB and who had a baseline CD4
count ,200 cells/mm
3 were on trimethoprim-sulfamethoxazole at
the time of ART initiation. Furthermore, 94 of 275 patients (34%)
who were not being treated for active TB and who did not have a
prior history of isoniazid preventive therapy (n=84) were given
isoniazid at baseline. Among 367 patients (91%) with non-missing
baseline hemoglobin values, the median hemoglobin level was
11.5 gm/dL (IQR 10.0–13.1).
Overall, 37 of 402 patients died (n=28, 7%) or were lost to
follow-up (n=9, 2%), and the median time-to-event among
patients who died was approximately 3 months (104 days, IQR 52
to 196 days). Table 2 shows the myriad diagnoses made in the
patients who died. Of the 37 deaths and losses to follow-up, 9
(24%) never returned for an ART refill after ART initiation (6
died and 3 were lost to follow-up). When expanding the outcome
to the composite definition including virologic failure and incident
OIs, 64 of 402 patients (16%) had an initial early adverse event
after ART initiation. Over half of these initial outcomes were
incident OIs (Table 1), and TB was the most common incident
OI (n=9). The median number of initial ART regimen days
dispensed was approximately 3 weeks (Table 1), and 75 of
402 (19%) patients had suboptimal early adherence (median
Antiretroviral Therapy Adherence and Early Outcomes
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with suboptimal adherence was 0.86 (IQR 0.76–0.94).
Table 3 shows relationships between baseline characteristics,
early adherence and early outcomes. As expected, patients with
the lowest CD4 counts were at increased risk of loss to follow-up
and death [27], although patients with OIs that were diagnosed at
baseline were not (Table 3). Adverse early outcomes were
significantly more common among those who had evidence of
suboptimal early adherence compared to those who did not
[16.0% vs 7.6%, RR 2.09 (95% CI 1.10–3.97) and 28.0% vs
13.1%, RR 2.13 (95% CI 1.35–3.36) for primary and secondary
outcomes, respectively] (Table 3). This relationship was un-
changed when only deaths and not losses to follow-up were
counted as outcomes [RR 2.11, 95% CI 1.00–4.47)]. No
confounders of these relationships were identified after evaluating
all of the variables listed in Table 1 (including baseline OIs and
baseline CD4 count evaluated as either a continuous or categorical
variable) and therefore adjusted analyses were not required. In
sensitivity analyses, reclassifying patients who initiated but never
refilled ART as adherent decreased the prevalence of suboptimal
adherence from 75 of 402 (19%) to 66 of 402 (16%) and changed
the adherence-outcome relationship so that it was no longer
statistically significant [RR 0.45 (0.14–1.42) and 1.17 (0.66–2.08)
for primary and secondary outcomes, respectively].
Using death or loss to follow-up as the outcome, the unadjusted
RR for suboptimal early adherence and this outcome of 2.09, and
the prevalence of suboptimal early adherence of 0.19, the PAR%
for early death or loss to follow-up from suboptimal early
adherence was 14.7%. For the composite outcome including OIs
and virologic failure, the PAR% was 17.7%.
Approximately two-thirds of patients who experienced early
outcomes had early adherence $95% [25 of 37 (68%) and 43 of 64
(67%) for primary and secondary outcomes, respectively], and the
high levels of adherence, even in those with early outcomes, were
reflected in high rates of virologic response. Overall, 355 of 402
(88%) achieved at least one viral load #400 copies/mL. Among the
56 patients who had initial adverse clinical outcomes that were not
virologic failure, 24 (43%) achieved one or more viral loads #400
copies/mL priortooronthedayoftheir initialadverseoutcome,10
(18%) achieved this degree of virologic response after the initial
outcome and 22 (39%) did not have a documented viral load at or
below this level. Of these 22, only 1 patient had documented
virologic failure, while the remaining 21 did not havefollow-upviral
load measurements. According to initial event type, 68% (23 of 34)
Table 1. Baseline characteristics, initial ART days dispensed, and initial adverse outcomes among patients in the prospective study
(n=402).
Female sex (n, %) 250 (62%)
Age (mean, range in years) 37 (range, 19 to 69)
Median CD4 count (cells/mm
3, IQR) 132 (IQR 73–180)
Median hemoglobin (gm/dL, IQR) 11.5 (IQR 10.0–13.1)
Any baseline WHO stage 3 or 4 OI (n, %) 89 (22%)
On anti-tubercular therapy (n, %) 52 (13%)
Baseline use of trimethoprim and sulfamethoxazole (n, %) among 366 eligible patients
a 328 (90%)
Baseline use of isoniazid preventive therapy (n, %) among among 275 eligible patients
b 94 (34%)
Initial ART regimen
AZT/3TC/EFV (n, %) 212 (53%)
AZT/3TC/NVP (n, %) 171 (43%)
d4T/3TC/EFV (n, %) 2 (1%)
d4T/3TC/NVP (n, %) 11 (3%)
Other (n, %) 6 (1%)
Initial ART days dispensed (median days, IQR) 20 (IQR 20–35)
Time to first ART refill (median days, IQR) 19 (IQR 14–30)
Suboptimal early adherence (n, %) 75 (19%)
Initial adverse outcomes - primary definition (n, %)
Lost to follow-up 9 (2%)
Death 28 (7%)
Initial adverse outcomes - expanded definition (n, %)
Virologic failure 8 (2%)
Incident OI 34 (8%)
Lost to follow-up 8 (2%)
Death 14 (3%)
OI=opportunistic illness; ART=combination antiretroviral therapy; IQR=inter-quartile range.
Percents may not add up to 100% due to rounding.
aPatients considered eligible for trimethoprim-sulfamethoxazole included patients being treated for active TB at baseline and patients not being treated for active TB
who had a baseline CD4 count ,200 cells/mm
3.
bPatients considered eligible for isoniazid preventive therapy included those who did not have known active TB and who did not have a prior history of isoniazid
preventive therapy.
doi:10.1371/journal.pone.0020010.t001
Antiretroviral Therapy Adherence and Early Outcomes
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e20010of those whose initial event was an incident OI, 57% (8 of 14) of
those whose initial and only recorded event was death, and 61% (34
of 56) of those with any initial non-virological adverse outcome had
one or more documented viral loads #400 copies/mL. The median
time between the closest viral load #400 copies/mL and the initial
adverse outcome among those who had non-virologic initialadverse
outcomes and measured viral loads was 3 days (IQR 68 days before
to 39 days after).
Discussion
This study, based on prospectively collected data from routine
clinical practice in Botswana, provides evidence that suboptimal
early ART adherence as measured by pharmacy refill data and pill
counts increases the risk of early adverse outcomes. In the primary
analysis, patients who had suboptimal early adherence during
approximately the first 21 days of ART had twice the risk of early
adverse outcomes as compared to patients whose adherence was
$95%. However, the proportion of early adverse outcomes
theoretically attributable to suboptimal early adherence in this
population, estimated as the PAR%, was relatively low (,20%),
and most early outcomes observed occurred in patients with high
levels of adherence and virologic suppression around the time of
their event. These results do not challenge the fact that adherence
is critically important in HIV care. However, they do indicate that
in many individuals living in similar settings with similarly
advanced HIV disease, even high levels of initial ART adherence
may not be enough to prevent emergent OIs, AIDS progression,
and death. The findings provide further data supporting the
revised WHO guidelines stressing the need to start ART at earlier
stages of HIV [28].
Our finding of increased risk of events in patients with
suboptimal adherence are consistent with a similar study from
Kenya which found an increased risk of death and loss to follow-
up in patients with lower adherence measured at 2 months post-
ART initiation [23] and more broadly with studies relating
adherence to survival over longer periods of time [17,29].
Considered together with studies indicating that both adherence
and early mortality are higher in sub-Saharan Africa compared to
industrialized countries [4,30], these data suggest that AIDS
progression and death in the setting of high levels of ART
adherence and virologic suppression is likely common in the
region. One reason for this is likely related to difficulty diagnosing
OIs that are present but untreated at baseline. Indeed, the finding
that the majority of non-death early adverse outcomes were
incident WHO grade 3 and 4 OIs indicates that improving
diagnosis and treatment of OIs around the time of ART initiation
has the potential to meaningfully reduce early adverse outcomes,
as has been suggested by others [31,32]. The fact that we did not
find an increased risk of early adverse outcomes among those who
Table 2. Primary Cause of Death Among Patients who Died
During the Study Period (n=28).
Cause of Death n (%)
Pulmonary Tuberculosis (PTB) 3 (11)
Hepatitis / Hepatic Encephalopathy 2 (7)
Meningitis (Unknown etiology) 2
a (7)
Cryptococcal Meningitis 1
b (4)
TB Adenitis 1 (4)
Pneumocystis Pneumonia (PCP) 1 (4)
Pneumonia 1 (4)
Pancytopenia / Severe Wasting Syndrome 1 (4)
AZT-induced Anemia 1
a (4)
Anemia 1
b (4)
Pericardial Effusion 1
b (4)
Encephalitis 1 (4)
Stroke / Multiple intracranial Abscesses 1 (4)
AIDS-related global dementing process
vs. Multiple brain lesion pathology
1( 4 )
Sepsis 1 (4)
Anasarca secondary to hypoalbuminemia 1 (4)
Unknown cause 8 (29)
aPatients had a diagnosis of Kaposi’s sarcoma which may have contributed to
death.
bPatients had a diagnosis of gastritis which may have contributed to death.
doi:10.1371/journal.pone.0020010.t002
Table 3. Unadjusted relative risks of adverse early outcomes according to patient characteristics.
Characteristic Group Primary outcome RR (95% CI) Secondary outcome RR (95% CI)
Sex Female (n=250)
Male (n=152)
18 (7.2%)
19 (12.5%)
Reference
1.74 (0.94–3.20)
34 (13.6%)
30 (19.7%)
Reference
1.45 (0.93–2.27)
Age #35 (n=202)
.35 (n=200)
17 (8.4%)
20 (10.0%)
Reference
1.19 (0.64–2.20)
28 (13.9%)
36 (18.0%)
Reference
1.30 (0.83–2.04)
Baseline CD4 count #50 (n=66)
51–150 (n=166)
.150 (n=167)
10 (15.2%)
14 (8.4%)
11 (6.6%)
2.30 (1.03–5.16)
1.28 (0.60–2.74)
Reference
13 (19.7%)
25 (15.1%)
24 (14.4%)
1.37 (0.74–2.53)
1.05 (0.62–1.76)
Reference
Baseline OI Absent (n=313)
Present (n=89)
28 (8.9%)
9 (10.1%)
Reference
1.13 (0.55–2.31)
45 (14.4%)
19 (21.3%)
Reference
1.48 (0.92–2.40)
Baseline active TB ATT Absent (n=357)
Present (n=45)
36 (10.1%)
1 (2.2%)
Reference
0.22 (0.03–1.57)
60 (16.8%)
4 (8.9%)
Reference
0.53 (0.20–1.39)
Initiated EFV-based ART No (n=188)
Yes (n=214)
15 (8.0%)
22 (9.2%)
Reference
1.29 (0.69–2.41)
26 (13.8%)
38 (17.8%)
Reference
1.28 (0.81–2.03)
Early adherence Optimal (n=327)
Suboptimal (n=75)
25 (7.6%)
12 (16.0%)
Reference
2.09 (1.10–3.97)
43 (13.1%)
21 (28.0%)
Reference
2.13 (1.35–3.36)
OI=opportunistic illness; ATT=anti-tubercular therapy for active tuberculosis; TMP/SMX=trimethoprim-sulfamethoxazole; EFV=efavirenz; RR=relative risk; Primary
outcome=death or loss to follow-up; Secondary outcome=incident OI, virologic failure, loss to follow-up or death.
doi:10.1371/journal.pone.0020010.t003
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from studies finding no increased risk of early mortality in patients
with known pulmonary TB at ART initiation [31,33] and further
supports efforts to detect and treat these conditions at the time of
starting ART. The high proportion of initial outcomes that were
OIs also warrants further consideration of ‘‘unmasking’’ immune
reconstitution inflammatory syndrome (IRIS) [34,35] as a
potentially important mechanism of early clinical deterioration.
Although recent data from sub-Saharan Africa indicate that fatal
IRIS is rare [8,36], patients may die before excessive inflammation
can be proven, particularly when inflammation occurs very early
after ART initiation and when studies are retrospective. Therefore
further evaluation of the role of very early inflammation in early
morbidity and mortality is warranted.
We did not prospectively grade drug toxicity, but many ART
drugs including zidovudine and nevirapine, which were initiated
by most and nearly half of the patients in this study, respectively,
have potentially fatal toxicities that could cause early mortality
despite and perhaps even due to high levels of adherence [37,38].
Severe drug toxicity in treatment centers in Africa is well-described
[39], and both zidovudine-associated anemia [9] and lactic
acidosis [40] may be more common in treated HIV-infected
Africans. More broadly, clarifying the mechanisms by which
adverse outcomes occur in the setting of high adherence and
virologic suppression, of which drug toxicity is one, should be
pursued.
Strengths of this study include a novel focus on early adherence
data using prospective prescription information, careful ascertain-
ment of data on incident OIs, active patient tracing to determine
outcomes, the sub-Saharan African setting and the availability of
routinely-collected viral load results, which enhanced our
evaluation. Inclusion of patients who initiated but never returned
for an ART refill in the primary analysis is another strength of the
study. Given that risk of early mortality after ART initiation in
resource-limited settings is highest very early after starting ART
[30], excluding individuals who are lost to follow-up or die early
after ART initiation excludes precisely those to whom the study
question is most relevant. In contrast, including these individuals
and using sensitivity analyses to provide an estimate of the
strongest and weakest likely relationships between early adherence
and early adverse outcomes provides a more comprehensive
evaluation of the association. While it is more reasonable to
assume that patients who initiated but never returned to refill ART
were not optimally adherent, it is also possible that some adhere up
to their final days and some discontinue very early, in which case
the true relative risk for early adherence and early adverse
outcomes is somewhat weaker, in an epidemiologic sense, than was
determined in the primary analysis.
Our study also has several limitations. For example, the
generalizability of our findings of relative risk and the low PAR%
could be limited if the patients agreeing to participate in this
study were more adherent compared to those being treated in
other settings. The overall rate of documented virologic response
in the cohort (88%) was slightly higher than pooled estimates
from sub-Saharan Africa (76%), suggesting that the study sample
demonstrated adherence that was relatively high but certainly not
outside of observed ranges [41]. Furthermore, we relied on
information obtained via routine care, and more clinical details
could have better informed the design of interventions aimed at
reducing early outcomes. Another limitation is that some patients
were lost to follow-up, and therefore we cannot be certain that
they experienced an adverse outcome after ART initiation.
However, most patients lost to follow-up were lost very soon after
ART initiation and shorter time to loss to follow-up is associated
with increased risk of mortality among those who are lost from
care [21]. Patients lost to follow-up from this public treatment
program have previously been shown to have a high rate of
mortality, which further suggests that those classified as lost in this
study had poor outcomes [19]. Furthermore, major bias due to
loss to follow-up did not occur because exclusion of patients who
were lost did not change the study findings. Another limitation
relates to the fact the cause of death was not known for 8 (29%) of
the patients who died, leaving open the possibility that these
individuals died from processes unrelated to their HIV infection
or their adherence to antiretroviral therapy. The low median
baseline CD4 count of the cohort and the fact that the majority of
patients for whom the cause of death was known died from OIs,
most commonly TB (n=4, 14%), suggests that most deaths were
HIV-related. Finally, our analysis of the relative risk of early
outcomes among those with suboptimal early adherence
inherently relates early outcomes occurring in the presence of
essentially any suboptimal adherence to the suboptimal adher-
ence itself. However, in cases where only a few doses were missed
suboptimal adherence is unlikely to be the sole cause of the
outcome. Viral loads decline logarithmically during a time period
equivalent to that which these patients most commonly were
supplied ART (i.e., 20 days) [42], and therefore the proportion of
early outcomes that could be prevented by a sole focus on
improving early adherence is likely even smaller than the PAR%
values would suggest.
In conclusion we found that suboptimal early adherence, while
associated with adverse outcomes, is a relatively uncommon
finding in patients experiencing early adverse outcomes. Given the
high contribution of early outcomes to morbidity and mortality in
ART treatment efforts in resource-limited settings, further
research to understand, identify, treat and prevent these outcomes
is needed.
Acknowledgments
We would like to thank the staff and patients of the Infectious Disease Care
Clinic in Gaborone, Botswana, without whom this project would not have
been possible.
Author Contributions
Conceived and designed the experiments: GPB KS RG APS. Performed
the experiments: RN GL TR KS APS. Analyzed the data: CWN SLB JNB
GB KTS. Wrote the paper: GPB KTS.
References
1. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R (2008) Early mortality
among adults accessing antiretroviral treatment programmes in sub-Saharan
Africa. AIDS 22: 1897–1908.
2. Marazzi MC, Liotta G, Germano P, Guidotti G, Altan AD, et al. (2008)
Excessive early mortality in the first year of treatment in HIV type 1-infected
patients initiating antiretroviral therapy in resource-limited settings. AIDS Res
Hum Retroviruses 24: 555–560.
3. Rosen S, Fox MP, Gill CJ (2007) Patient retention in antiretroviral ther-
apy programs in sub-Saharan Africa: a systematic review. PLoS Med 4:
e298.
4. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, et al. (2006) Adherence
to antiretroviral therapy in sub-Saharan Africa and North America: a meta-
analysis. JAMA 296: 679–690.
5. Park WB, Choe PG, Kim SH, Jo JH, Bang JH, et al. (2007) One-year adherence
to clinic visits after highly active antiretroviral therapy: a predictor of clinical
progress in HIV patients. J Intern Med 261: 268–75.
6. Nakanjako D, Kiragga A, Ibrahim F, Castelnuovo B, Kamya MR, et al. (2008)
Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on
antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical
significance. AIDS Res Ther 5: 23.
Antiretroviral Therapy Adherence and Early Outcomes
PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e200107. Bourgarit A, Carcelain G, Martinez V, Lascoux C, Delcey V, et al. (2006)
Explosion of tuberculin-specific Th1-responses induces immune restoration
syndrome in tuberculosis and HIV co-infected patients. AIDS 20: 1–7.
8. Murdoch DM, Venter WD, Feldman C, Van Rie A (2008) Incidence and risk
factors for the immune reconstitution inflammatory syndrome in HIV patients in
South Africa: a prospective study. AIDS 22: 601–610.
9. Ssali F, Stohr W, Munderi P, Reid A, Walker AS, et al. (2006) Prevalence,
incidence and predictors of severe anaemia with zidovudine-containing regimens
in African adults with HIV infection within the DART trial. Antivir Ther 11:
741–749.
10. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, et al. (2006) HIV
treatment response and prognosis in Europe and North America in the first
decade of highly active antiretrovial therapy: a collaborative analysis. Lancet
368: 451–458.
11. Chene G, Sterne JA, May M, Costagliola D, Ledgerber B, et al. (2003)
Prognostic importance of initial response in HIV-1 infected patients starting
potent antiretroviral therapy: analysis of prospective studies. Lancet 362:
679–686.
12. McMahon JH, Jordan MR, Kelley K, Bertagnolio S, Hong SY, et al. (2011)
Pharmacy adherence measures to assess adherence to antiretroviral therapy:
review of the literature and implications for treatment monitoring. Clin Infect
Dis 52: 493–506.
13. Bisson GP, Rowh A, Weinstein R, Gaolathe T, Frank I, et al. (2008)
Antiretroviral failure despite high levels of adherence: discordant adherence-
response relationship in Botswana. J Acquir Immune Defic Syndr 49: 107–110.
14. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, et al. (2006) Scaling
up of highly active antiretroviral therapy in a rural district of Malawi: an
effectiveness assessment. Lancet 367: 1335–1342.
15. Muyingo SK, Walker AS, Reid A, Munderi P, Gibb DM, et al. (2008) Patterns
of individual and population-level adherence to antiretroviral therapy and risk
factors for poor adherence in the first year of the DART trial in Uganda and
Zimbabwe. J Acquir Immune Defic Syndr 48: 468–475.
16. Spire B, Carrieri P, Sopha P, Protopopescu C, Prak N, et al. (2008) Adherence
to antiretroviral therapy in patients enrolled in a comprehensive care program in
Cambodia: a 24-month follow-up assessment. Antivir Ther 13: 697–703.
17. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, et al. (2006) Adherence to
highly active antiretroviral therapy assessed by pharmacy claims predicts survival
in HIV-infected South African adults. J Acquir Immune Defic Syndr 43: 78–84.
18. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, et al. (2009)
Antiretroviral therapy adherence, virologic and immunologic outcomes in
adolescents compared with adults in southern Africa. J Acquir Immune Defic
Syndr 51: 65–71.
19. Bisson GP, Gaolathe T, Gross R, Rollins C, Bellamy S, et al. (2008)
Overestimates of survival after HAART: implications for global scale-up efforts.
PLoS One 3: e1725.
20. Wester CW, Bussmann H, Avalos A, Ndwapi N, Gaolathe T, et al. (2005)
Establishment of a public antiretroviral treatment clinic for adults in urban
Botswana: lessons learned. Clin Infect Dis 40: 1041–1044.
21. Brinkhof MW, Pujades-Rodriguez M, Egger M (2009) Mortality of patients lost
to follow-up in antiretroviral treatment programmes in resource-limited settings:
systematic review and meta-analysis. PLoS One 4: e5790.
22. World Health Organization (2005) Interim WHO Clinical Staging of HIV/
AIDS and HIV/AIDS Case Definitions for Surveillance: African Region.
Geneva: World Health Organization. Available at: http://www.who.int/hiv/
pub/guidelines/clinicalstaging.pdf, accessed March 15, 2011.
23. Karcher H, Omondi A, Odera J, Kunz A, Harms G (2007) Risk factors for
treatment denial and loss to follow-up in an antiretroviral treatment cohort in
Kenya. Trop Med Int Health 12: 687–694.
24. Laurent C, Diakhate N, Gueye NF, Toure MA, Sow PS, et al. (2002) The
Senegalese government’s highly active antiretroviral therapy initiative: an 18-
month follow-up study. AIDS 16: 1363–1370.
25. Rockhill B, Newman B, Weinberg C (1998) Use and misuse of population
attributable fractions. Am J Public Health 88: 15–19.
26. Rothman KJ, Greenland S, Lash TL (2008) Modern epidemiology. Philadel-
phia: Wolters Kluwer Health/Lippincott Williams & Wilkins. x, 758 p.
27. Egger M, May M, Chene G, Phillips AN, Ledergerber B, et al. (2002) Prognosis
of HIV-1-infected patients starting highly active antiretroviral therapy: a
collaborative analysis of prospective studies. Lancet 360: 119–129.
28. World Health Organization (2010) Antiretroviral therapy for HIV infection in
adults and adolescents: Recommendations for a public health approach. 2010
Revision. Geneva: World Health Organization. Available at: http://whqlibdoc.
who.int/publications/2010/9789241599764_eng.pdf, accessed March 20, 2011.
29. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, et al. (2002) Intermittent use
of triple-combination therapy is predictive of mortality at baseline and after 1
year of follow-up. AIDS 16: 1051–1058.
30. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006)
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy:
comparison between low-income and high-income countries. Lancet 367:
817–824.
31. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, et al. (2006)
Risk factors for high early mortality in patients on antiretroviral treatment in a
rural district of Malawi. AIDS 20: 2355–2360.
32. Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, et al. (2010)
Tuberculosis during the first year of antiretroviral therapy in a South African
cohort using an intensive pretreatment screening strategy. AIDS 24: 1323–1328.
33. Westreich D, MacPhail P, Van Rie A, Malope-Kgokong B, Ive P, et al. (2009)
Effect of pulmonary tuberculosis on mortality in patients receiving HAART.
AIDS 23: 707–715.
34. Haddow LJ, Easterbrook PJ, Mosam A, Khanyile NG, Parboosing R, et al.
(2009) Defining immune reconstitution inflammatory syndrome: evaluation of
expert opinion versus 2 case definitions in a South African cohort. Clin Infect
Dis 49: 1424–1432.
35. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, et al. (2008)
Tuberculosis-associated immune reconstitution inflammatory syndrome: case
definitions for use in resource-limited settings. Lancet Infect Dis 8: 516–523.
36. Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, et al. (2009)
Cause-specific mortality and the contribution of immune reconstitution
inflammatory syndrome in the first 3 years after antiretroviral therapy initiation
in an urban African cohort. Clin Infect Dis 49: 965–972.
37. Hester EK, Peacock JE, Jr. (1998) Profound and unanticipated anemia with
lamivudine-zidovudine combination therapy in zidovudine-experienced patients
with HIV infection. AIDS 12: 439–440.
38. Leng K, Lonsdorf A, Hartmann M (2008) Fatal outcome of nevirapine-
associated toxic epidermal necrolysis. Int J STD AIDS 19: 642–643.
39. Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, et al. (2003)
Virologic and immunologic outcomes and programmatic challenges of an
antiretroviral treatment pilot project in Abidjan, Cote d’Ivoire. AIDS 17 Suppl
3: S5–15.
40. Wester CW, Okezie OA, Thomas AM, Bussmann H, Moyo S, et al. (2007)
Higher-than-expected rates of lactic acidosis among highly active antiretroviral
therapy-treated women in Botswana: preliminary results from a large
randomized clinical trial. J Acquir Immune Defic Syndr 46: 318–322.
41. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM
(2010) Virological follow-up of adult patients in antiretroviral treatment
programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 10:
155–166.
42. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, et al. (2007)
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor
raltegravir as part of combination therapy in treatment-naive patients with HIV-
1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr
46: 125–133.
Antiretroviral Therapy Adherence and Early Outcomes
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20010